C.E. Credits

The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


FEB 26, 2020

Drug Discovery & Development 2020



LabRoots and the Drug Discovery planning committee are pleased to announce the 3rd Annual Drug Discovery & Development Virtual Conference. LabRoots will host this online-only event on February 26, 2020. The Drug Discovery planning committee will carefully plan and select speakers that best represent the key challenges, opportunities, and issues in the current landscape. These industry leaders will discuss the advancements, challenges and successes of discovery and develop new medications and therapies

The theme for this years event is State of the Art and will include the following tracks and topics:

New Practices in Early Phase Drug Discovery >>

  • Alternative In-Vitro Approaches
  • Novel In-Vivo Techniques
  • CRISPR-Cas9 as a Drug Discovery Tool
  • Organ-on-a-Chip and 3D Cultures in Screening

Advancement of Biomarkers in Drug Development >>

  • Liquid Biopsies
  • Precision Medicine
  • PK/PD Modelling and Simulation
  • Receptor Occupancy

Modern Approaches to Clinical Development >>

  • Case Study Keynote
  • Combination Therapies
  • CAR-T/Immunotherapy
  • Precision Medicine
  • Direct to Patient Clinical Trials

Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event.  The webinars will be available for unlimited on-demand viewing.  This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.

Like the 2019 conference, this event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.


Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2020 Drug Discovery & Development Virtual Event. Submission is free. Submit your abstract here.

Continuing Education
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.

Use #LRdrug to follow the conversation!


Speakers

Show Resources
You May Also Like
JAN 01, 2019 8:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JAN 01, 2019 8:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Luminex's xMAP® Technology enables the evaluation of up to 500 analytes simultaneously in a single well, known as multiplexing. xMAP Technology uses color-coded microspheres as the substrate...
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2020 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
MAR 25, 2020 8:30 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
MAR 25, 2020 8:30 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
 LabRoots is pleased to announce the 3rd Annual Cannabis Sciences Virtual Event. LabRoots will host the event March 25, 2020. The Cannabis Sciences planning comm...
SEP 08, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 08, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 1st Annua...
MAY 20, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
MAY 20, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Welcome to the 4th Annual Laboratory Automation & Informatics Virtual Event; a free virtual conference for professionals interested in the most recent technologies for today’s labs...
MAY 06, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
MAY 06, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is please to announce our 2nd Forensic Sciences Virtual onMay 6, 2020. The exciting field of forensic sciences is focused on a blend of biology, ch...
Presentations

Starting with our 2020 Drug Discovery & Development virtual event, LabRoots is introducing our new agenda format.  We will be offering a full agenda of scheduled presentations throughout the day of the event; including Keynotes, Panels and Sponsored speakers.  We will also be offering unlimited presentations available for immediate On-Demand viewing when the doors to our virtual event open.  The content of our presentations will be delivered by experts in industry and academia.  We hope you enjoy our new format!

  • FEB 26, 2020 1:30 PM PST
    Automated cell separation for drug discovery assays
    Speaker: Josh Mahlios, PhD
    Sponsored By: Miltenyi Biotec
  • FEB 26, 2020 12:00 PM PST
    Characterizing the role of B cells in Response to Immunotherapy with the NanoString GeoMx Platform
    Speaker: Sarah Warren, PhD
    Sponsored By: NanoString Technologies
  • FEB 26, 2020 10:30 AM PST
    QIAGEN CLC Genomics Workbench 20 - scalable software for NGS data analysis
    Speaker: Leif Schauser, PhD
    Sponsored By: QIAGEN
  • FEB 26, 2020 9:00 AM PST
    CRISPR Based Screening: Advantages of Transcriptional Activators and Inhibitors
    Speaker: Andrew Ravanelli, PhD
    Sponsored By: MilliporeSigma
  • FEB 26, 2020 7:30 AM PST
    Keynote Presentation: Emerging Drug Combinations: Evolution From Pre-Clinical Discovery to Clinical Development
    Speaker: Khyati Shah, PhD
  • FEB 26, 2020 6:00 AM PST
    Keynote Presentation: Discovery and Development of a Novel First-in-Class Resuscitative Agent
    Speaker: Professor Anil Gulati, MD, PhD
  • 3D-Micro Tissues in Translational Toxicology and Disease Modelling
    Speaker: Armin Wolf, PhD
  • CK18 as a Biomarker in NASH Clinical Trials
    Speaker: Jessica Tuohy, PhD
  • Generation of expanded primary liver cells
    Speaker: Astrid Nörenberg, PhD
  • Human Tissue models for better therapies
    Speaker: Sebastiaan Trietsch, PhD
  • Measuring What Matters: Proliferation and Cell Death Biomarkers for Oncology Research
    Speaker: Olivia Stricker, PhD
  • Microfabricated Human Liver Tissues for Drug Development
    Speaker: Salman Khetani, PhD
  • Microphysiological Systems for Human Focused Drug Discovery
    Speaker: Tomasz Kostrzewski, PhD
  • Organoids: A Revolutionary New Tool for Drug Screening
    Speaker: Rekha Pal, PhD
  • Uncovering the mechanism of stress-resistant DNA replication in cancer cells using a modern single-molecule technique
    Speaker: Chames Kermi, PhD, PharmD
  • Using 3D cell culture models and high content confocal imaging to evaluate efficacy and expose toxic liabilities in the drug development pipeline
    Speaker: Erin Edwards, PhD
  • Vancomycin: How might Urinary Biomarkers and Precision Dosing create Precision Medicine for the most frequently utilized antibiotic in the hospital?
    Speaker: Marc Scheetz, PharmD, MSc, FCCP, BCPS AQ-ID
  • New Practices in Early Phase Drug Discovery
  • 3D-Micro Tissues in Translational Toxicology and Disease Modelling
    Speaker: Armin Wolf, PhD
  • Generation of expanded primary liver cells
    Speaker: Astrid Nörenberg, PhD
  • Human Tissue models for better therapies
    Speaker: Sebastiaan Trietsch, PhD
  • Microfabricated Human Liver Tissues for Drug Development
    Speaker: Salman Khetani, PhD
  • Microphysiological Systems for Human Focused Drug Discovery
    Speaker: Tomasz Kostrzewski, PhD
  • Organoids: A Revolutionary New Tool for Drug Screening
    Speaker: Rekha Pal, PhD
  • Using 3D cell culture models and high content confocal imaging to evaluate efficacy and expose toxic liabilities in the drug development pipeline
    Speaker: Erin Edwards, PhD
  • FEB 26, 2020 12:00 PM PST
    Characterizing the role of B cells in Response to Immunotherapy with the NanoString GeoMx Platform
    Speaker: Sarah Warren, PhD
    Sponsored By: NanoString Technologies
  • FEB 26, 2020 1:30 PM PST
    Automated cell separation for drug discovery assays
    Speaker: Josh Mahlios, PhD
    Sponsored By: Miltenyi Biotec
  • Advancement of Biomarkers in Drug Development
  • CK18 as a Biomarker in NASH Clinical Trials
    Speaker: Jessica Tuohy, PhD
  • Measuring What Matters: Proliferation and Cell Death Biomarkers for Oncology Research
    Speaker: Olivia Stricker, PhD
  • Vancomycin: How might Urinary Biomarkers and Precision Dosing create Precision Medicine for the most frequently utilized antibiotic in the hospital?
    Speaker: Marc Scheetz, PharmD, MSc, FCCP, BCPS AQ-ID
  • Modern Approaches to Clinical Development
  • Uncovering the mechanism of stress-resistant DNA replication in cancer cells using a modern single-molecule technique
    Speaker: Chames Kermi, PhD, PharmD
  • FEB 26, 2020 6:00 AM PST
    Keynote Presentation: Discovery and Development of a Novel First-in-Class Resuscitative Agent
    Speaker: Professor Anil Gulati, MD, PhD
  • FEB 26, 2020 7:30 AM PST
    Keynote Presentation: Emerging Drug Combinations: Evolution From Pre-Clinical Discovery to Clinical Development
    Speaker: Khyati Shah, PhD
  • FEB 26, 2020 9:00 AM PST
    CRISPR Based Screening: Advantages of Transcriptional Activators and Inhibitors
    Speaker: Andrew Ravanelli, PhD
    Sponsored By: MilliporeSigma
  • FEB 26, 2020 10:30 AM PST
    QIAGEN CLC Genomics Workbench 20 - scalable software for NGS data analysis
    Speaker: Leif Schauser, PhD
    Sponsored By: QIAGEN
Speakers

  • Professor Anil Gulati, MD, PhD
    Chairman & Chief Executive Officer of Pharmazz, Inc.; Adjunct Professor, Colleges of Pharmacy and Graduate Studies, Midwestern University; Department of Bioengineering, University of Illinois
    Biography
      Anil Gulati, MD, PhD is Chairman and Chief Executive Officer of Pharmazz, Inc. and is an adjunct Professor at the Colleges of Pharmacy and Graduate Studies, Midwestern University and Department of Bioengineering at University of Illinois at Chicago, Illinois. He is a consultant to Advocate Lutheran General Children's Hospital. Dr. Gulati is the Scientific Reviewer, United States Defense Medical Research and Development Program, Combat Casualty Care Research Program 2016 and 2017. He is recipient of Outstanding Faculty Award 2017, Paul R Dawson Biotechnology Award 2014 and Littlejohn Award 2014. Dr. Gulati is a United States Fulbright Scholar 2008-2009 and winner of International Ranbaxy Research Award 2007. He has ~300 peer reviewed publications and guided researches of more than 100 graduate students, medical residents and research fellows. He has 5,446 citations, h-index of 41, i10-index of 147, research gate score of 46.58. He has 52 issued patents of which 24 has been issued by the US patent office, and rest by patent offices in Europe, India, China, Japan, Australia and Canada. Some of the discoveries related to endothelin made by him are undergoing clinical phase II trials in the United States and clinical phase III trials in India. Dr. Gulati founded Pharmazz, Inc. and its subsidiary Pharmazz India Private Limited which is developing his inventions for critical care medicine, resuscitation of shock, stroke and complication of diabetes. He was an elected Fellow of American College of Clinical Pharmacology and was Co-Chair of the ET-14: World Endothelin Conference 2015, Savannah, Georgia.
    • Khyati Shah, PhD
      Post Doctoral Research Scholar at University of California, San Francisco
      Biography
        Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in breast cancer. Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.
      • Erin Edwards, PhD
        Head of Services, Visikol, Inc.
        Biography
          Erin holds a bachelor's degree from Brown University in Biomedical Engineering and a PhD from Georgia Tech in Bioengineering. With a background in topics ranging from immuno-oncology to cell mechanics, Erin has a passion for using advanced cell culture models to study complex disease mechanisms and evaluate new therapeutics. Erin brings over 8 years of in vitro assay development experience to Visikol as the Head of Services, where she focuses on developing and executing assays to help biotech and pharmaceutical Clients study disease, evaluate therapeutics, and mitigate toxicity risks.
        • Chames Kermi, PhD, PharmD
          Postdoctoral Fellow, Chemical and Systems Biology, Stanford University School of Medicine
          Biography
            When I obtained my Pharmacist (Pharm. D) degree several years ago, I asked myself what I really wanted to do and what career path would allow me to reach my goals. The answer was clear and obvious in my mind: I wanted to do research and work on understanding cancer development and finding new ways to fight cancer. To this end, I joined the faculty of pharmacy of Montpellier, France, where I obtained a Master's degree in research and development of pharmaceutical drugs. At that time I worked preclinical drug development at Sanofi pharmaceuticals in France. I was in charge of establishing new in vitro/in silico models for study of drugs pharmacokinetics. After that, the next step was to obtain a PhD degree. I joined Dr. Domenico MAIORANO's group in Montpellier, France, and I worked mainly on establishing a functional interaction between the DNA damage tolerance (DDT) and the DNA damage response (DDR) in cells. My work uncovered a novel mechanism responsible for the silencing of the DNA damage checkpoint in early embryos, and explained how translesion DNA polymerases are recruited to DNA damage foci. After a successful PhD concluded by obtaining the Best Young Scientist Award in Cancer research, I joined Professor Karlene Cimprich's lab at Stanford to acquire new experience, new way of working and thinking, and to learn new techniques. Most importantly, this lab is one of top labs in the field of replication stress and replication fork reversal. During my postdoc, I learned new innovative techniques; high-content microscopy (QIBC), single-molecule methods (DNA spreading and DNA combing), high throughput CRIPR-Cas9 genome-wide screening, and bioinformatics. I worked on understanding how cancer cells tolerate replication stress. I am particularly interested in studying several aspects of replication stress in cancer stem cells. This sub-population of cancer cells characterized by its amazingly high resistance to stress inducing agents but the basis for this is unknown. The next step in my career will be going back to biotech company to do a more transnational work in order to discover new innovative therapies to cure/regress cancer. Immune therapy is one of the very promising ways to do that.
          • Salman Khetani, PhD
            Associate Professor, Department of Bioengineering, University of Illinois at Chicago
            Biography
              Dr. Salman Khetani received his dual Bachelor of Science degrees in electrical engineering and biomedical engineering from Marquette University, and Masters and PhD degrees in bioengineering from University of California at San Diego (UCSD). He was a Jacobs fellow and National Science Foundation graduate fellow at UCSD. After postdoctoral research at MIT in the laboratory of Professor Sangeeta Bhatia, Dr. Khetani co-founded and directed research at Hepregen Corporation to commercialize his bioengineered liver inventions for pharmaceutical drug development. In 2011, Dr. Khetani returned to academia, first to Colorado State University and then in 2015 as associate professor of Bioengineering at the University of Illinois at Chicago, where his 'Microfabricated Tissue Models' laboratory (http://mtm.uic.edu/) designs and implements novel engineered tissues for drug screening, investigations of human diseases, and regenerative medicine. Dr. Khetani's 50+ publications in journals such as Hepatology, Nature Biotechnology, and PNAS have been cited more than 4000 times with an h-index of 30. Lastly, Dr. Khetani's research has been funded over the last 12 years via ~$6M in grants from the NIH, NSF, DOD, FDA, and the NSF CAREER award.
            • Tomasz Kostrzewski, PhD
              Director, Biology, CN Bio Innovations Limited
              Biography
                Dr Tomasz Kostrzewski is Director of Biology at CN Bio with more than 10 years of experience in molecular and cellular biology research. Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation. At Imperial College London he completed both an MRes and PhD in the department of Cell and Molecular Biology. He has significant experience in advanced (3D) mammalian cell culture, gene expression analysis and immune cell function. Additionally, he has previous experience of working in biopharmaceutical drug discovery and development with GlaxoSmithKline. In 2017, he was promoted to head of biology at CN Bio and is responsible for biological model development and collaborative research projects. TK has published more than seven peer-reviewed scientific articles in the last three years.
              • Josh Mahlios, PhD
                Senior Marketing Product Manager, Miltenyi Biotec
                Biography
                  Josh Mahlios is a Senior Marketing Product Manager at Miltenyi Biotec, responsible for cell separation technologies and immunology focused applications. In these roles, he drives the awareness and adoption of the reagents and instrumentation specifically developed for both basic and translational researchers investigating the immune system. Prior to joining Miltenyi Biotec in 2016, Josh was a postdoctoral scholar at Stanford University.
                • Astrid Nörenberg, PhD
                  Managing Director, upcyte technologies GmbH
                  Biography
                    Astrid studied Biological Engineering (B.Sc.) and Biotechnology (M.Sc.) at the Universities of Applied Sciences in Frankfurt and Darmstadt, Germany, respectively. In her PhD she worked with different cell types of the liver in a spin off Start-up in Heidelberg and continued in the same company in the role of Sales and BD. In 2015 she founded upcyte technologies. The company provides expanded primary cells, media and services for drug discovery. By using the upcyte® protocol non-dividing primary cells are pushed back into proliferation without altering their most relevant tissue-specific characteristics.
                  • Rekha Pal, PhD
                    Director, Scientific Engagement, Crown Bioscience, Inc.
                    Biography
                      Rekha is a trained cancer biologist with a focus on preclinical cancer therapeutics, immune-oncology, cancer signaling, and tumor microenvironment. She earned her Ph.D. in Biochemistry from Central Drug Research Institute, India. She joined the University of Pittsburgh as a postdoctoral researcher and moved onto research faculty. She has extensively worked in stem cell biology and translational cancer research using patient's blood, tumor and bone marrow samples with a correlation of clinical data for the targeted biomarker identification with the drug treatment. She joined National Surgical Adjuvant Breast and Bowel project (NSABP), a clinical trial supportive group to develop strategies for preclinical evaluation of test agents to support NSABP's phase I/II clinical trials for colon and breast cancer. She also led the effort of organoids generation from the PDX tumor tissue to screen drug or drugs combination as personalized medicine. Rekha represented NSABP as a translational research committee member on B-50 Katherine-B027938 Roche study. Rekha role at CrownBio is to direct scientific engagement with pharmaceutical company, academic scientists, and clients. She helps in decision making with goal of high scientific input in study design and model execution. Exchange scientific information for existing and new opportunities between BD and the scientific team, generate protocols, study designs and proposals to define projects/ studies.
                    • Andrew Ravanelli, PhD
                      Senior R&D Scientist, Genome and Epigenome Editing, MilliporeSigma
                      Biography
                        Andrew obtained his Ph.D. in Cell Biology from Duke University, where he used mouse and zebrafish models to dissect cellular mechanisms of early tissue formation. He completed a postdoctoral fellowship in Pediatrics at the University of Colorado School of Medicine where he used pharmacological and genetic manipulations coupled with 4D imaging to investigate cell fate specification in the brain and spinal cord. Andrew joined MilliporeSigma in 2016 and has been developing novel mechanisms to modulate gene expression using CRISPR-Cas9.
                      • Leif Schauser, PhD
                        Director, Global Product Management, QIAGEN
                        Biography
                          Leif Schauser holds a Ph.D. in Plant Molecular Genetics from Aarhus University, Denmark. He did his postdoctoral training in Norwich, UK, before working as a professor in Bioinformatics at Aarhus University. In 2013 Leif joined CLC bio, just before its acquisition by QIAGEN.
                        • Marc Scheetz, PharmD, MSc, FCCP, BCPS AQ-ID
                          Professor, Midwestern University in the Chicago College of Pharmacy, Director of the Pharmacometric Center of Excellence at Midwestern University
                          Biography
                            Marc Scheetz attained a Doctorate of Pharmacy from Butler University, earned a Masters of Science in Clinical Investigation degree at Northwestern University, and completed his pharmacy practice residency and an infectious diseases fellowship at Northwestern Memorial Hospital. Dr. Scheetz is a Professor at Midwestern University in the Chicago College of Pharmacy and holds a joint appointment in the Department of Pharmacology, College of Graduate Studies. Dr. Scheetz is the Director of the Pharmacometric Center of Excellence at Midwestern University. He currently practices clinically as an infectious diseases pharmacist at Northwestern Memorial Hospital in downtown Chicago, IL and serves as the Director for the Post-Doctoral Fellowship Program in Infectious Diseases Pharmacotherapy. Dr. Scheetz has authored a number of original research manuscripts and review articles in the area of anti-infective pharmacokinetics and pharmacodynamics and currently serves as a reviewer for several infectious diseases, pharmacy, and medical journals. His primary research interest lies in the interface of the pharmacokinetic/pharmacodynamic interaction (i.e. between antimicrobials, pathogens, and hosts). He is particularly interested in assessing modifiable pharmacologic variables in the treatment of infectious diseases and identifying optimal exposures against the backdrop of toxicity. His group studies toxicology in the laboratory as well as through clinical data modeling. Dr. Scheetz is actively engaged in local and national leadership positions and formerly served as a member of the FDA Antimicrobial Drugs Advisory Committee.
                          • Olivia Stricker, PhD
                            Commercial Business Development Manager, Diapharma Group, Inc.
                            Biography
                              Olivia Stricker earned her PhD from the University of Cincinnati, where she focused much of her time working in cell signaling and immunology assays. After graduating, she left the bench to work for a recombinant protein manufacturer and ultimately acted as their Chief Scientific Officer. In her position there, she explored the needs of the stem cell and immunology markets for purified cytokines, chemokines and growth factors. Now, at Diapharma, Olivia is heading up business development and is working to help commercialize unique biomarkers in the US market. She enjoys Jazzercise, weekend baking and long walks on the beach.
                            • Sebastiaan Trietsch, PhD
                              Chief Technology Officer, Mimetas -The Organ on a Chip Company
                              Biography
                                Bas Trietsch is the CTO and co-founder of MIMETAS. He is co-inventor of the OrganoPlate, optimized it towards a mass manufacturable product and enabled establishment of Mimetas' production facility. He developed the initial tissue models on the OrganoPlate and continues to support model and assay development in the OrganoPlate®. As Chief Technology Officer he currently drives the continued innovation and development of the OrganoPlate, related equipment and cell based products. Bas holds a PhD in biopharmaceutical sciences from Leiden University and co-authored over 40 peer reviewed publications and patents.
                              • Jessica Tuohy, PhD
                                Scientific Product Manager, DiaPharma Group, Inc.
                                Biography
                                  Dr. Jessica Tuohy is the Scientific Product Manager for Diapharma's biomarker portfolio, which includes assays for studying liver injury in the context of non-alcoholic fatty liver disease, alcoholic hepatitis, metabolic syndrome, and drug-induced liver injury. Jessica received her PhD in Pharmacology from the University of Colorado Health Sciences Center, where she was trained in mass spectrometry of lipids. She contributed to some of the early work in lipidomics in two research positions - first at Cell Therapeutics in Seattle, and subsequently at Vanderbilt University in Nashville, as part of the LIPID-MAPS consortium. Jessica joined Diapharma in 2005. She spent eleven years as the Western Territory Account Manager with a focus on assays for hemostasis, thrombosis and anticoagulation monitoring before she transitioned to her current role as brand ambassador and technical specialist for the company's hepatology and toxicology product lines. When she is not working, Jessica is busy trying to keep up with her three kids - two human and one furry.
                                • Sarah Warren, PhD
                                  Senior Director of Advanced Applications, NanoString Technologies
                                  Biography
                                    Sarah Warren is the Senior Director of Translational Science at NanoString Technologies where she leverages multiplexed, molecular profiling technologies to address key research areas in oncology, immunology, and beyond. Her role enables her to work with academics, biopharmas, and clinicians to identify unmet needs in translational research and create novel products for transcriptional and proteomic profiling. She is also active in the immuno-oncology research community to promote the science and application of cancer immunotherapy to improve patient outcomes. Prior to joining NanoString, she was a founder and director of research at Oncofactor Corp., a biotech startup focused on developing therapeutics which targeted novel immune checkpoints. She has a PhD in immunology from the University of Washington and performed her graduate work at the Institute for Systems Biology.
                                  • Armin Wolf, PhD
                                    Chief Scientific Officer, InSphero AG
                                    Biography
                                      Armin Wolf is Chief Scientific Officer at InSphero AG in ZH, Switzerland and Professor of Toxicology at the Technical University of Kaiserslautern, Germany. He is an accomplished pharmaceutical R&D executive and board-certified toxicologist with more than 30 years cumulative experience at Novartis and Janssen. Armin offers a first-hand perspective on the challenges facing the pharmaceutical industry
                                    Sponsored by

                                    For information on becoming a sponsor or exhibitor, please click here.


                                    Posters

                                    POSTER SUBMISSION GUIDELINES

                                    Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.


                                    SUBMIT YOUR ABSTRACT

                                    Enter the following information to this Submission Form:

                                    • Poster Title
                                    • Your Name
                                    • Your Institution
                                    • Your Email
                                    • Abstract describing the poster


                                    All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

                                    If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

                                    Questions? Email Posters@LabRoots.com

                                    LabRoots Policy

                                    Committee

                                    To download the Program Committee brochure here.


                                    • Annette Gilchrist

                                      An Associate Professor with Midwestern University, and adjunct faculty member at Northwestern University Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she ...

                                      See more See less
                                    • Matthew Flegal

                                      Matt entered the research field over 20 years ago as a lab animal technician at the TSI/Mason contract research facility. He has worked at both contract facilities such as TSI and OREAD Biosafety as well in industry at Pharmacia, Pfizer, and Sanofi-Aventis. During that period he ...

                                      See more See less
                                    • Khyati Shah

                                      Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ...

                                      See more See less
                                    • Martin Shaw

                                      Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as ...

                                      See more See less
                                    • Matthew Shipton

                                      Leading Novabiosis' primary cell business, Matthew brings to the Company a skill for implementing sales-driven business strategies, an extensive track record of meeting and surpassing targeted sales objectives, and a passion for translating customer needs into solutions that ...

                                      See more See less
                                    Help

                                    General LabRoots Questions

                                    For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  

                                    Virtual Events and Webinars

                                    Supported Configurations

                                    • Operating System Internet Explorer Firefox Chrome Safari
                                      Vista IE8+ FF10+ Chrome15+
                                      Windows 7 IE8+ FF10+ Chrome15+
                                      Windows 8 IE10 FF10+ Chrome15+
                                      Mac OS X   FF10+ Chrome15+ Safari5.1+
                                    • Cookie settings: session cookies enabled
                                    • Browser configuration must have JavaScript enabled
                                    • Adobe Flash player 10.2 or later

                                    To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                    Internet Connection

                                    • A minimum of 100Kbps is recommended for audio-only events
                                    • A minimum of 300Kbps is recommended for speaker on-video events

                                    Computer Equipment

                                    • Screen Resolution: Minimum 1024x768
                                    • Video Card: 65,000 colors minimum
                                    • Sound card and speakers (or headphones) for hearing webcast in full format
                                    • Audio Card: 16-bit minimum
                                    • RAM: 512MB of free RAM

                                    Firewall Protocol

                                    • HTTP on port 80 or HTTPS on port 443
                                    • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                    • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                    Work-At-Home Attendees

                                    • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                    For A Seamless Experience

                                    When using a mobile device, FREE Mobile Apps are available:

                                    - For viewing Webinars:

                                    - For viewing Virtual Events

                                    Attendee Guide

                                    • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                    Virtual Event and Webinar Support:

                                    Continuing Education (CME/CE) Support

                                    Loading Comments...
                                    Show Resources